Literature DB >> 2859169

Quantitative account of propranolol metabolism in urine of normal man.

T Walle, U K Walle, L S Olanoff.   

Abstract

A recent study, identifying several sulfate conjugates, appears to have led to a full qualitative account of propranolol metabolism in man. The objective of the present investigation was to determine the quantitative fate of propranolol, including the relationship between the primary metabolic pathways, i.e. glucuronidation, side-chain oxidation and ring oxidation. Single 80-mg oral doses of propranolol together with [3H]propranolol were administered to seven normal subjects. Urinary metabolites were determined by HPLC with radiometric detection after hydrolysis of glucuronic acid conjugates and fractionation by solvent extraction. About 90% of the dose was recovered in urine. Twelve metabolites accounted for 91% of the recovered dose. When examining the metabolites based on the primary metabolic pathways, 17% of the dose (range, 10-25%) was going through glucuronidation, 41% (range, 32-50%) through side-chain oxidation, and 42% (range, 27-59%) through ring oxidation. These data show that the net elimination of propranolol is largely due to oxidative metabolism. The relative contribution of the primary pathways is well reflected by the four major propranolol metabolites, i.e. propranolol glucuronide, naphthoxylactic acid, and the glucuronic acid and sulfate conjugates of 4'-hydroxypropranolol. These observations should greatly facilitate future studies of the biochemical mechanisms of propranolol disposition.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2859169

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  18 in total

Review 1.  Drug metabolism in the nasal mucosa.

Authors:  M A Sarkar
Journal:  Pharm Res       Date:  1992-01       Impact factor: 4.200

2.  Absorption of propranolol in humans following oral, jejunal, and ileal administration.

Authors:  A Buch; W H Barr
Journal:  Pharm Res       Date:  1998-06       Impact factor: 4.200

3.  Partial metabolic clearances as determinants of the oral bioavailability of propranolol.

Authors:  T Walle; U K Walle; L S Olanoff; E C Conradi
Journal:  Br J Clin Pharmacol       Date:  1986-09       Impact factor: 4.335

Review 4.  The polymorphic oxidation of beta-adrenoceptor antagonists. Clinical pharmacokinetic considerations.

Authors:  M S Lennard; G T Tucker; H F Woods
Journal:  Clin Pharmacokinet       Date:  1986 Jan-Feb       Impact factor: 6.447

5.  The effect of age on diurnal variation in the pharmacokinetics of propranolol in hypertensive subjects.

Authors:  T Shiga; A Fujimura; T Tateishi; K Ohashi; A Ebihara
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

Review 6.  Clinical significance of genetic influences on cardiovascular drug metabolism.

Authors:  L Arcavi; N L Benowitz
Journal:  Cardiovasc Drugs Ther       Date:  1993-06       Impact factor: 3.727

7.  Influence of beta-adrenoceptor antagonists on the pharmacokinetics of rizatriptan, a 5-HT1B/1D agonist: differential effects of propranolol, nadolol and metoprolol.

Authors:  M R Goldberg; D Sciberras; M De Smet; R Lowry; L Tomasko; Y Lee; T V Olah; J Zhao; K P Vyas; R Halpin; P H Kari; I James
Journal:  Br J Clin Pharmacol       Date:  2001-07       Impact factor: 4.335

8.  Propranolol oxidation by human liver microsomes--the use of cumene hydroperoxide to probe isoenzyme specificity and regio- and stereoselectivity.

Authors:  S V Otton; E M Gillam; M S Lennard; G T Tucker; H F Woods
Journal:  Br J Clin Pharmacol       Date:  1990-11       Impact factor: 4.335

9.  Generation of HepG2 Cells with High Expression of Multiple Drug-Metabolizing Enzymes for Drug Discovery Research Using a PITCh System.

Authors:  Ryosuke Negoro; Mitsuki Tasaka; Sayaka Deguchi; Kazuo Takayama; Takuya Fujita
Journal:  Cells       Date:  2022-05-18       Impact factor: 7.666

10.  Identification of human CYP isoforms involved in the metabolism of propranolol enantiomers--N-desisopropylation is mediated mainly by CYP1A2.

Authors:  K Yoshimoto; H Echizen; K Chiba; M Tani; T Ishizaki
Journal:  Br J Clin Pharmacol       Date:  1995-04       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.